JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Haloperidol is an antipsychotic drug that has similar actions to the antipsychotic medicine phenothiazine [1].
Haloperidol has been reported to play a role as an inverse agonist of dopamine. In addition, Haloperidol has been found to be highlt potent neuroleptic by relieving nervous through the depression of nerve function. Besides, Haloperidol has shown about 50-fold potency than chiorpromazine, the other antipsychotic drug. Haloperidol has shown beneficial effects in the treatment of delusions and hallucinations. These effects are mainly achieved through blockage of dopamine receptors in the mesocortex and limbic system. Haloperidol has been revealed to prevent the effects of dopamine in the nigrostriatal pathways, which probably explains the associated side effects such as akathisia and dystonias[1].
References:[1] Dr Ananya Mandal, MD .Haloperidol Pharmacology.
Animal models
Male Sprague-Dawley rats, 225 ~ 250 g
Dosage form
0, 0.01, 0.05, 0.1 or 0.5 mg/kg
Administered subcutaneously
Applications
In rats, the dopamine agonist apomorphine (APO) caused a significant decrease in prepulse inhibition (PPI) of the acoustic startle response, which could be reversed in a dose-dependent manner by haloperidol. PPI of the acoustic startle response is a measure of sensorimotor gating that is impaired in both schizophrenic patients and in rats treated with dopamine agonists. The ability of antipsychotics such as haloperidol to restore PPI in APO-treated rats correlates significantly with their clinical potency.
Note
The technical data provided above is for reference only.
References:
1. Swerdlow NR, Geyer MA. Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. Pharmacol Biochem Behav. 1993 Mar;44(3):741-4.
